Manning & Napier Group's NBIX Position Overview
Manning & Napier Group (via Manning & Napier Advisors LLC) currently holds 2 shares of Neurocrine Biosciences, Inc. (NBIX) worth $257, representing 0.00% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 2 quarters.
Based on recent 13F filings, Manning & Napier Group has initiated a new position in NBIX, representing a fresh investment thesis on this company. Largest reduction occurred in Q1 2026, reducing 20 shares.
Analysis based on 13F filings available since 2013 Q2
Manning & Napier Group's Neurocrine Biosciences (NBIX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Neurocrine Biosciences (NBIX) Trades by Manning & Napier Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -20 | Reduce 90.91% | 2 | $128.50 |
| Q4 2025 | +22 | New Buy | 22 | $140.95 |
Manning & Napier Group's Neurocrine Biosciences Investment FAQs
Manning & Napier Group first purchased Neurocrine Biosciences, Inc. (NBIX) in Q4 2025, acquiring 22 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Manning & Napier Group has held Neurocrine Biosciences, Inc. (NBIX) for 2 quarters since Q4 2025.
Manning & Napier Group's largest addition to Neurocrine Biosciences, Inc. (NBIX) was in Q4 2025, adding 22 shares worth $3,101.
According to the latest 13F filing for Q1 2026, Manning & Napier Group's firm, Manning & Napier Advisors LLC, owns 2 shares of Neurocrine Biosciences, Inc. (NBIX), valued at approximately $257.
As of the Q1 2026 filing, Neurocrine Biosciences, Inc. (NBIX) represents approximately 0.00% of Manning & Napier Group's publicly disclosed stock portfolio, making it one of their key holdings.
Manning & Napier Group's peak holding in Neurocrine Biosciences, Inc. (NBIX) was 22 shares, as reported at the end of Q4 2025.